Trading Report: Today, Zacks: Ascendis Pharma A/S (ASND) Given $29.67 Consensus Target Price by Brokerages

Today, Zacks: Ascendis Pharma A/S (ASND) Given $29.67 Consensus Target Price by Brokerages

Ascendis Pharma A/S (NASDAQ:ASND) has been assigned a consensus broker rating score of 1.00 (Strong Buy) from the four analysts that provide coverage for the company, Zacks Investment Research reports. Four equities research analysts have rated the stock with a strong buy rating.

Brokers have set a 12-month consensus price target of $29.67 for the company and are anticipating that the company will post ($0.69) earnings per share for the current quarter, according to Zacks. Zacks has also given Ascendis Pharma A/S an industry rank of 71 out of 265 based on the ratings given to its competitors.

ASND has been the topic of a number of analyst reports. Wedbush initiated coverage on shares of Ascendis Pharma A/S in a research report on Monday, September 26th. They set an “outperform” rating and a $34.00 target price on the stock. Zacks Investment Research upgraded shares of Ascendis Pharma A/S from a “hold” rating to a “buy” rating and set a $22.00 target price on the stock in a research report on Tuesday, October 4th. Leerink Swann restated a “buy” rating on shares of Ascendis Pharma A/S in a research report on Friday, September 2nd. Finally, TheStreet upgraded shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research report on Tuesday, September 6th.

Shares of Ascendis Pharma A/S (NASDAQ:ASND) opened at 20.635 on Monday. Ascendis Pharma A/S has a one year low of $11.92 and a one year high of $21.79. The company has a 50 day moving average of $0.00 and a 200-day moving average of $0.00.

Hedge funds have recently modified their holdings of the company. Sphera Funds Management LTD. increased its stake in shares of Ascendis Pharma A/S by 0.6% in the third quarter. Sphera Funds Management LTD. now owns 263,500 shares of the company’s stock worth $5,296,000 after buying an additional 1,700 shares during the period. Baker BROS. Advisors LP purchased a new stake in shares of Ascendis Pharma A/S during the third quarter worth $14,985,000. Finally, RA Capital Management LLC increased its stake in shares of Ascendis Pharma A/S by 7.9% in the third quarter. RA Capital Management LLC now owns 3,681,491 shares of the company’s stock worth $73,998,000 after buying an additional 268,634 shares during the period. 43.55% of the stock is owned by institutional investors.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop a pipeline of long-acting prodrug therapies that address markets with unmet medical needs. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications.

Related posts

Leave a Comment